Metabolic Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Metabolic therapy encompasses interventions that target energy metabolism dysfunction in neurodegenerative diseases. Brain hypometabolism is a hallmark of neurodegeneration, with impaired glucose utilization, mitochondrial dysfunction, and reduced ATP production contributing to neuronal death [1].
The ketogenic diet shifts brain metabolism from glucose to ketone bodies (β-hydroxybutyrate, acetoacetate), providing an alternative fuel source.
| Ketone | Brain Transport | Energy Yield |
|---|---|---|
| β-Hydroxybutyrate | MCT1 transporter | 4.5 ATP/carbon |
| Acetoacetate | Passive diffusion | 3.5 ATP/carbon |
Mechanisms:
Clinical Evidence in AD:
Clinical Evidence in PD:
| Approach | Protocol | Mechanism |
|---|---|---|
| Calorie Restriction | 20-30% caloric reduction | Autophagy induction |
| Intermittent Fasting | 16:8 or 5:2 protocols | Metabolic switching |
| Time-Restricted Eating | Daily eating window | Circadian optimization |
| Fasting-Mimicking Diet | 5-day monthly cycle | Stem cell activation |
Mechanisms:
| Property | Value |
|---|---|
| Source | Coconut oil, palm kernel oil |
| Key Molecules | C8 (caprylic acid), C10 (capric acid) |
| Brain Entry | Direct via MCT1 transporter |
| Conversion | Liver to ketone bodies |
Clinical Evidence:
| Property | Value |
|---|---|
| Role | Gluconeogenesis substrate |
| CNS Entry | Monocarboxylate transporters |
| Energy | Glycolysis intermediate |
Clinical Evidence:
| Property | Value |
|---|---|
| Target | Pyruvate dehydrogenase kinase |
| Effect | Activates PDH complex |
| Status | Phase 2 trials |
Clinical Evidence:
Metabolic Targets:
Clinical Trials:
| Trial | Intervention | Phase | Status |
|---|---|---|---|
| NCT02561468 | Ketogenic diet | 2 | Completed |
| NCT03472664 | MCT oil | 2 | Completed |
| NCT05338411 | Fasting-mimicking diet | 2 | Recruiting |
Outcomes:
Metabolic Targets:
Clinical Trials:
| Trial | Intervention | Phase | Status |
|---|---|---|---|
| NCT03962712 | Ketogenic diet | 2 | Completed |
| NCT03795727 | DCA | 2 | Completed |
Outcomes:
Metabolic Targets:
Clinical Trials:
Metabolic Targets:
Clinical Evidence:
| Biomarker | Use | Method |
|---|---|---|
| Fasting glucose | Metabolic status | Blood test |
| HbA1c | Long-term glucose | Blood test |
| Insulin | Insulin sensitivity | ELISA |
| Ketone bodies | Ketosis | Blood test |
| Lactate | Glycolysis | CSF/blood |
| FDG-PET | Cerebral glucose | PET imaging |
| Combination | Rationale | Expected Benefit |
|---|---|---|
| Ketogenic + Exercise | Synergistic mitochondrial biogenesis | Enhanced neuroprotection |
| Fasting + Exercise | Autophagy activation | Protein clearance |
| MCT + Exercise | Enhanced ketone uptake | Cognitive benefit |
| Combination | Rationale | Status |
|---|---|---|
| Ketogenic + Acetylcholinesterase inhibitors | Multiple mechanisms | Adjunctive |
| Fasting + Metformin | Autophagy + metabolic | Preclinical |
| DCA + CoQ10 | Mitochondrial support | Phase 2 |
Common Side Effects:
Contraindications:
Risks:
Contraindications:
The study of Metabolic Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Cunnane SC, et al. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition. 2011;27(1):3-20.
[2] Mosconi L, et al. Brain glucose hypometabolism and cognitive impairment in AD. Ann Neurol. 2008;64(3):271-273.
[3] Schapira AH. Mitochondrial dysfunction in Parkinson's disease. Cell Death Dis. 2014;5(5):e1281.
[4] Paoli A, et al. Beyond weight loss: the potential of ketogenic diet for neurodegenerative diseases. Front Neurol. 2019;10:1013.
[5] Mattson MP, et al. Fasting: molecular mechanisms and clinical applications. Cell. 2014;156(1-2):62-78.